Austria

CHSH advised Frequentis AG on its IPO in Vienna and Frankfurt

CHSH has advised Frequentis AG as Lead Counsel in connection with its IPO in Frankfurt and Vienna.

Cerha Hempel Spiegelfeld Hlawati has advised Frequentis AG, a leading international provider of safety-critical communication and information solutions with headquarters in Vienna, as Lead Counsel in connection with its IPO in Frankfurt and Vienna.

Already in the run-up to the "going public", approximately 907,000 shares were privately placed with selected investors as part of a pre-IPO. In addition, 3,000,000 bearer shares were subscribed in Germany and Austria in the course of the IPO. Thereof, 1,200,000 new shares stem from a capital increase of the company and 1,800,000 shares (300,000 as part of a greenshoe option) were provided by the majority shareholder Johannes Bardach. The dual listing took place on 14 May 2019: The shares of Frequentis AG are traded both in the Regulated Market (General Standard) of the Frankfurt Stock Exchange and in the Regulated Market (Prime Market) of the Vienna Stock Exchange.

The Austrian company Frequentis, headquartered in Vienna, is a leading international provider of communication and information systems for control centers with safety-critical tasks. Frequentis has a worldwide network of branches, subsidiaries and local representatives in over 50 countries. Products and solutions of Frequentis are deployed at more than 25,000 workplaces and in around 140 countries.

As Lead Counsel, CHSH was responsible for the structuring and legal support with respect to corporate, capital market and stock exchange law. The scope of advice included the carrying out of a due diligence review, the structuring and implementation of the pre-IPO private placement phase, the drafting of contractual documentation with banks and other stakeholders, the preparation of the capital market prospectus as well as all related regulatory matters.

The CHSH team was jointly headed by the Partners Dr. Clemens Hasenauer and Dr. Volker Glas. Further, the team consisted of the Partners Dr. Harald Stingl and Lorenz Pracht, the Senior Associate Christian Aichinger and the Associates Dr. Alexander Reich-Rohrwig, Benedikt Svoboda and Florian Dafinger.